Lymphoma Working Party (LWP)
Study type:
Study number:
84032223
Type of treatment:
Autologous
Diseases:
Non-Hodgkin’s Lymphoma (NHL)
Short title:
Auto SCT for NKTC Lymphoma as Consolidation & Relapse treatment
Primary objective:
Progression-free survival (PFS)
Key inclusion criteria:
- Histologically confirmed diagnosis by local pathologist of Natural Killer/T-cell lymphoma (extranodal, nodal type, nasal type or not specified)
- First autologous hematopoietic stem cell transplantation (HSCT) between 2011 and 2022.
-Age ≥ 18 years at first auto HSCT
- First autologous hematopoietic stem cell transplantation (HSCT) between 2011 and 2022.
-Age ≥ 18 years at first auto HSCT
Country:
All EBMT member countries
Principal investigator:
Philipp Berning
EBMT Study coordinator:
Thani Said Ali Ahmed Nassila
Study coordinator email:
thani.nassila@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Histological report
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results